An Innovative Concept in Pharmaceutical Drug Development
- PDF / 389,616 Bytes
- 7 Pages / 504 x 719 pts Page_size
- 51 Downloads / 221 Views
An Innovative Concept in Pharmaceutical Drug Development Rolf F. Tiggemann and Hermann Sabel Drug Information Journal 1997 31: 119 DOI: 10.1177/009286159703100118 The online version of this article can be found at: http://dij.sagepub.com/content/31/1/119
Published by: http://www.sagepublications.com
On behalf of:
Drug Information Association
Additional services and information for Drug Information Journal can be found at: Email Alerts: http://dij.sagepub.com/cgi/alerts Subscriptions: http://dij.sagepub.com/subscriptions Reprints: http://www.sagepub.com/journalsReprints.nav Permissions: http://www.sagepub.com/journalsPermissions.nav Citations: http://dij.sagepub.com/content/31/1/119.refs.html
>> Version of Record - Jan 1, 1997 What is This?
Downloaded from dij.sagepub.com at UNIVERSITE LAVAL on October 2, 2014
0092-8615/97 Copyright 0 1997 Drug Information Association Inc.
Drug Information Journal. Vol. 31. pp. 119-124. 1997 Printed in the USA. All rights reserved.
AN INNOVATIVE CONCEPT IN PHARMACEUTICAL DRUG DEVELOPMENT ROLFF. TIGGEMANN, PHD C & C Pharma Consulting Ltd., Arlesheim, Switzerland
HERMANN SABEL,DSc Professor for Economic Sciences, and Director, Institute of Business Administration (111). University of Bonn, Bonn, Germany
The pharmaceutical market arena is changing faster than in the past which forces pharmaceutical companies to adapt their drug development accordingly. In order to move more products to market faster; innovative operations and processes should be explored and implemented. Both a team-driven environment and a simplified operational framework significantly add value to the overall drug development process, cutting down development cycle times. The strategic drug development (SDD)concept emanates from the idea of consequently following the experience curve wirh a clear focus on competing against time. SDD has been used since I990 in 14 new chemical entity (NCE) early phase clinical development projects. This paper presents a decrease in development cycle time achieved by an accumulation of experience, summarizes significant time advantages by learning, and thus, indicates options to manifest durable competitive advantages in the area of drug development. Key Words: Team-driven drug development; Development cycle time; Experience curve; Time gain by learning
INTRODUCTION SINCE MARKET SUCCESS is volatile, pharmaceutical companies must strive to become better than the average and to differentiate themselves from the “rest.” This considerably pertains to the complex area of drug development by which research results should efficiently be translated into profit and growth. In the long term, success largely depends on the ability to be innovative in every respect, which requires a high degree of flexibility and openness toward any change. Drug developers need to constantly
Reprint address: Rolf F. Tiggemann, PhD, C & C Pharma Consulting Ltd., P.O.Box 02, D-79427. Eshbach-Freiburg, Germany.
create precisely the right environment at the right time in order to remain detectives rathe
Data Loading...
